First BioVentrix Revivent® System Clinical Patients Sustain 39.6% Improvement in Heart Function at One Year
6/27/2013 9:52:47 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SAN RAMON, Calif.--(BUSINESS WIRE)--BioVentrix, pioneer of the Less Invasive Ventricular Enhancement™ (LIVE™) procedure for the treatment of heart failure, announced today publication of baseline and 12-month comparative data demonstrating the durability of its Revivent Myocardial Anchoring System in the first 11 patients treated with the device. Published in the European Journal of Cardio-Thoracic Surgery (EJCTS), these patients sustained a mean reduction in left ventricular end-systolic volume index (LVESVI), the key prognostic measure for heart failure, to 43.9 mL/m2, well below the 60mL/m2 threshold recently defined as providing a survival benefit in heart failure patients.1,2 The Company also announced that the number of heart failure centers trained to perform the LIVE procedure has expanded to 20 leading centers throughout Western Europe.
Help employers find you! Check out all the jobs and post your resume.
comments powered by